Amanda Nickles Fader1, James Java2, Thomas C Krivak3, Robert E Bristow4, Ana I Tergas5, Michael A Bookman6, Deborah K Armstrong5, Edward J Tanner5, David M Gershenson7. 1. Johns Hopkins Medical Institutions, Baltimore, MD, USA. Electronic address: afader1@jhmi.edu. 2. Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY, USA. 3. Magee-Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA, USA. 4. University of California Irvine, Orange, CA, USA. 5. Johns Hopkins Medical Institutions, Baltimore, MD, USA. 6. Arizona Cancer Center, Tucson, AZ, USA. 7. University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA.
Abstract
OBJECTIVES: The study objective was to determine the prognostic significance of serum CA-125 levels in patients with grade 1 serous ovarian carcinoma (SOC) enrolled in a Phase III study. METHODS: An ancillary analysis of a phase III study of women with advanced epithelial ovarian cancer treated with carboplatin/paclitaxel versus triplet or sequential doublet regimens. Grade 1 SOC was used as a surrogate for low-grade serous carcinoma. RESULTS: Among 3686 enrolled patients, 184 (5%) had grade 1 disease and CA-125 levels available. For those with grade 1 SOC, the median patient age was 56.5; 87.3% had Stage III disease. Median follow-up was 102 months and there was no difference in pre-chemotherapy CA-125 by treatment arm (P=0.91). Median pretreatment CA-125 for those with grade 1 SOC was lower (119.1) than for patients with grade 2-3 SOC (246.7; P<0.001). In those with grade 1, pretreatment CA-125 was not prognostic of outcome. However, patients with CA-125 levels that normalized after cycle 1, 2 or 3 were 60-64% less likely to experience disease progression as compared to those who never normalized or normalized after 4 cycles (P ≤ 0.024). Normalization of CA-125 levels before the second cycle was negatively associated with death, with a HR of 0.45 (P=0.025). CONCLUSIONS: Pretreatment CA-125 level was significantly lower in women with grade 1 SOC compared to those with high-grade SOC. While pretreatment CA-125 was not associated with survival, serial CA-125 measurements during chemotherapy treatment were prognostic, with normalization before the second chemotherapy cycle associated with a decreased risk of death.
OBJECTIVES: The study objective was to determine the prognostic significance of serum CA-125 levels in patients with grade 1 serous ovarian carcinoma (SOC) enrolled in a Phase III study. METHODS: An ancillary analysis of a phase III study of women with advanced epithelial ovarian cancer treated with carboplatin/paclitaxel versus triplet or sequential doublet regimens. Grade 1 SOC was used as a surrogate for low-grade serous carcinoma. RESULTS: Among 3686 enrolled patients, 184 (5%) had grade 1 disease and CA-125 levels available. For those with grade 1 SOC, the median patient age was 56.5; 87.3% had Stage III disease. Median follow-up was 102 months and there was no difference in pre-chemotherapy CA-125 by treatment arm (P=0.91). Median pretreatment CA-125 for those with grade 1 SOC was lower (119.1) than for patients with grade 2-3 SOC (246.7; P<0.001). In those with grade 1, pretreatment CA-125 was not prognostic of outcome. However, patients with CA-125 levels that normalized after cycle 1, 2 or 3 were 60-64% less likely to experience disease progression as compared to those who never normalized or normalized after 4 cycles (P ≤ 0.024). Normalization of CA-125 levels before the second cycle was negatively associated with death, with a HR of 0.45 (P=0.025). CONCLUSIONS: Pretreatment CA-125 level was significantly lower in women with grade 1 SOC compared to those with high-grade SOC. While pretreatment CA-125 was not associated with survival, serial CA-125 measurements during chemotherapy treatment were prognostic, with normalization before the second chemotherapy cycle associated with a decreased risk of death.
Authors: P.M. Fayers; G. Rustin; R. Wood; A. Nelstrop; R.C.F. Leonard; P. Wilkinson; D. Cruickshank; E.J. McAllister; C.W.E. Redman; D. Parker; I.V. Scott; M.L. Slevin; J.E. Roulston Journal: Int J Gynecol Cancer Date: 1993-09 Impact factor: 3.437
Authors: Deborah K Armstrong; Brian Bundy; Lari Wenzel; Helen Q Huang; Rebecca Baergen; Shashikant Lele; Larry J Copeland; Joan L Walker; Robert A Burger Journal: N Engl J Med Date: 2006-01-05 Impact factor: 91.245
Authors: Peter G Rose; Stacy Nerenstone; Mark F Brady; Daniel Clarke-Pearson; George Olt; Stephen C Rubin; David H Moore; James M Small Journal: N Engl J Med Date: 2004-12-09 Impact factor: 91.245
Authors: F M Muggia; P S Braly; M F Brady; G Sutton; T H Niemann; S L Lentz; R D Alvarez; P R Kucera; J M Small Journal: J Clin Oncol Date: 2000-01 Impact factor: 44.544
Authors: Nathalie L G Sieben; Patricia Macropoulos; Guido M J M Roemen; Sandra M Kolkman-Uljee; Gert Jan Fleuren; Rifat Houmadi; Tim Diss; Bretta Warren; Mudher Al Adnani; Anton P M De Goeij; Thomas Krausz; Adrienne M Flanagan Journal: J Pathol Date: 2004-03 Impact factor: 7.996
Authors: John Farley; William E Brady; Vinod Vathipadiekal; Heather A Lankes; Robert Coleman; Mark A Morgan; Robert Mannel; S Diane Yamada; David Mutch; William H Rodgers; Michael Birrer; David M Gershenson Journal: Lancet Oncol Date: 2012-12-21 Impact factor: 41.316
Authors: R C Bast; T L Klug; E St John; E Jenison; J M Niloff; H Lazarus; R S Berkowitz; T Leavitt; C T Griffiths; L Parker; V R Zurawski; R C Knapp Journal: N Engl J Med Date: 1983-10-13 Impact factor: 91.245
Authors: Felix Zeppernick; Laura Ardighieri; Charlotte G Hannibal; Russell Vang; Jette Junge; Susanne K Kjaer; Rugang Zhang; Robert J Kurman; Ie-Ming Shih Journal: Am J Surg Pathol Date: 2014-12 Impact factor: 6.394
Authors: David M Gershenson; Diane C Bodurka; Robert L Coleman; Karen H Lu; Anais Malpica; Charlotte C Sun Journal: J Clin Oncol Date: 2017-02-21 Impact factor: 44.544
Authors: Michal Mleko; Kazimierz Pitynski; Elzbieta Pluta; Aleksandra Czerw; Katarzyna Sygit; Beata Karakiewicz; Tomasz Banas Journal: Cancer Manag Res Date: 2021-07-09 Impact factor: 3.989